Kate Madigan, MD, serves as Chief Medical Officer of Hemab. With over 20 years of clinical hematology expertise, she has a wealth of experience in designing and leading clinical programs spanning early to late stages in oncology and rare diseases. Prior to Hemab, Kate served as the Chief Medical Officer at Syndax Pharmaceuticals, where she led the U.S. FDA approval of Revuforj and Niktimvo. Her extensive leadership experience includes roles such as Senior Medical Director at Alnylam Pharmaceuticals and Medical Director within Biogen’s Rare Disease Innovation Unit. Kate also held academic appointments at the University of California San Diego and Rady Children’s Hospital-San Diego. She earned her M.D. from the Keck School of Medicine at the University of Southern California.